Dosed first participant with OV4071, the first-ever oral potassium-chloride cotransporter 2 (KCC2) direct activator, in May 2026 in a Phase 1 study with healthy volunteers OV329 showed favorable safety, tolerability, pharmacokinetics (PK), and drug exposure at higher doses, supporting the planned advancement of Phase 2 and proof-of-concept studies Announced development expansion of OV329 into additional pediatric indications of tuberous sclerosis complex (TSC) seizures and infantile spasms (IS), conditions for which GABA-aminotransferase (GABA-AT) inhibition is a validated mechanism Strengthened balance sheet, raising $60.0 million of gross proceeds in March 2026 PIPE financing with participation from leading healthcare investors Received $53.9 million in gross proceeds upon full exercise of Series A warrants in connection with October...

SUPRAME Phase 3 interim and final analysis for PRAME cell therapy, anzu-cel, expected to be triggered in 2026, advancing toward the Company’s first commercial launch planned in 2027Multiple key clinical data sets expected in 2026 across the portfolio, including four clinical-stage cell therapy and bispecific candidates targeting cutaneous and uveal melanoma, gynecologic cancers (ovarian and uterine), head and neck cancer, and other solid tumor indicationsPhase 1 data readout with second-generation PRAME cell therapy, IMA203CD8, to be presented at the 2026 ASCO meeting, focusing on anti-tumor activity in gynecologic cancersPhase 1b clinical data from PRAME bispecific, IMA402, as monotherapy and initial data in combination with an immune checkpoint inhibitor at RP2D range expected in 2H 2026First Phase 1 trial evaluating the combination...

SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) — SOLV Energy, Inc. (“SOLV” or the “Company”) (Nasdaq: MWH), a leading provider of infrastructure services to the power industry, today announced financial results for the first quarter ended March 31, 2026. Financial Summary(in $ millions except percentages) Three Months Ended March 31,  2026   2025Revenue 677   408Gross Profit 119   59Gross Margin 17.6%   14.5%Net Loss1 (27)   (1)       Adjusted Gross Profit2 124   59Adjusted Gross Margin2 18.4%   14.5%Adjusted EBITDA 93   341) Represents Net Loss before Non-Controlling Interest2) Adjusted Gross Profit and Adjusted Gross Margin exclude the impact of the allocation of non-cash compensation expense to cost of revenue First Quarter 2026 Financial and Recent Business HighlightsRevenue of $677 million, up...

U.S. Food and Drug Administration (FDA) review of oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission remains on track, with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026 Commercial readiness activities continue in anticipation of the potential commercial launch of OLCMOUNTAIN VIEW, Calif., May 12, 2026 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the first quarter ended March 31, 2026, and provided a business update. “As we approach the June 29th PDUFA target action date, we remain optimistic about the potential approval of OLC and focused on preparations for the subsequent launch of OLC,” said Shalabh Gupta, M.D., Chief Executive...

Conference call will be held today, Tuesday, May 12 at 9:00 am ET CARMEL, Ind., May 12, 2026 (GLOBE NEWSWIRE) — NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the first quarter period ended March 31, 2026. 1Q26 Financial HighlightsRevenues increased 80% year over year to $1.6M, reflecting the AMA Category I CPT® code assignment for Percutaneous Electrical Nerve Field Stimulation (PENFS) effective January 1, 2026, substantially increasing payor coverage. Expanded gross margin by 200 basis points and improved operating loss by 24% year over year as more IB-Stim® devices were sold at full price due to the recently secured Category I CPT® Code. Cash...

– First-ever FDA approved PROTAC supports the further development and potential of Arvinas’ pipeline – – Announced FDA Approval of VEPPANU™ (vepdegestrant) for the treatment of ESR1m, ER+/HER2- advanced breast cancer – – Announced selection of Rigel Pharmaceuticals for the exclusive global rights to VEPPANU – – Presented ARV-102 (LRRK2 degrader) Phase 1 clinical data in patients with Parkinson’s disease demonstrating reduction in endolysosomal and neuroinflammatory biomarkers implicated in Parkinson’s disease and progressive supranuclear palsy – – Presented ARV-6723 (HPK1 degrader) preclinical data at the American Associated of Cancer Research Annual meeting demonstrating the potential to overcome immune checkpoint inhibitor resistance in solid tumors – – Initiated dosing with ARV-027 (polyQ-AR degrader) in Phase 1 healthy volunteer...

Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF) The Company expects to file the IND for PRT13722, first-in-class highly-selective oral KAT6A degrader, by mid-2026 with Phase 1 study initiation in ER+ breast cancer anticipated in the 2H 2026 Presented preclinical data demonstrating differentiated profile of PRT13722, at the American Association for Cancer Research (AACR) Annual Meeting 2026 Appointed Charles Morris, M.D. as Chief Medical Officer Current cash runway expected into second quarter of 2028 based on preliminary estimates, driven by previously announced underwritten offering with gross proceeds of $90 million WILMINGTON, Del., May 12, 2026 (GLOBE NEWSWIRE) — Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage...

ZUG, Switzerland, May 12, 2026 (GLOBE NEWSWIRE) — Lithium Argentina AG (“Lithium Argentina” or the “Company”) (TSX: LAR) (NYSE: LAR) today announced its first quarter 2026 results. Unless otherwise stated, results are presented in United States dollars on a 100% basis. Sam Pigott, Lithium Argentina’s CEO, commented: “Cauchari-Olaroz continues to deliver exceptional performance, sustaining production near design capacity for a second consecutive quarter while delivering first-quarter cash operating costs below $5,400 per tonne. This operational consistency is translating directly into cash flow, with the operation expected to convert over 90% of first-quarter EBITDA into cash in 2026. “Building on this foundation, the Stage 2 expansion at Cauchari-Olaroz is progressing well, and we intend to grow organically by leveraging...

Q1 2026 key highlightsNNIT’s financial performance and order entry were below initial expectations reflecting continued geopolitical turmoil and sustained customer caution, particularly within the life science IT consulting industry as seen throughout 2025. In response, targeted growth initiatives have been launched to strengthen sales execution and accelerate revenue generation across regions. Reported group revenue declined 9.0% to DKK 422.5m, equal to constant currency revenue growth of -7.3%. In the first quarter, the group EBIT excl. special items ended at DKK 1.1m, corresponding to a group EBIT margin excl. special items of 0.3%. The lower profitability primarily reflects reduced revenue levels, alleviated by cost-reducing initiatives carried out during 2025 and progressing to plan. Additional actions are being implemented to align...

New Record for Q1 Revenue, Strong Gross Margins and Net Income COSTA MESA, Calif., May 12, 2026 (GLOBE NEWSWIRE) — Ducommun Incorporated (NYSE: DCO) (“Ducommun” or the “Company”) today reported results for its first quarter ended April 4, 2026. First Quarter 2026 RecapNet Revenue was $209.0 million, an increase of 9% over Q1 2025* Gross margin of 26.9%, year-over-year growth of 70 bps Net income of $9.9 million (increase of 607% year-over-year) or $0.64 per diluted share, and 4.7% of revenue, up 400 bps year-over-year Non-GAAP adjusted net income of $11.7 million (increase of 232% year-over-year), or $0.75 per diluted share Adjusted EBITDA of $35.4 million (increase of 19% year-over-year), or 16.9% of revenue, up 150 bps year-over-year“An excellent quarter and strong start to 2026 for Ducommun. Our team continued to make great...